The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies

Bing Yu, Krista A. Zanetti, Marinella Temprosa, Demetrius Albanes, Nathan Appel, Clara Barrios Barrera, Yoav Ben-Shlomo, Eric Boerwinkle, Juan P. Casas, Clary Clish, Caroline Dale, Abbas Dehghan, Andriy Derkach, A. Heather Eliassen, Paul Elliott, Eoin Fahy, Christian Gieger, Marc J. Gunter, Sei Harada, Tamara HarrisDeron R. Herr, David Herrington, Joel N. Hirschhorn, Elise Hoover, Ann W. Hsing, Mattias Johansson, Rachel S. Kelly, Chin Meng Khoo, Mika Kivimäki, Bruce S. Kristal, Claudia Langenberg, Jessica Lasky-Su, Deborah A. Lawlor, Luca A. Lotta, Massimo Mangino, Loïc Le Marchand, Ewy Mathe, Charles E. Matthews, Cristina Menni, Lorelei A. Mucci, Rachel Murphy, Matej Oresic, Eric Orwoll, Jennifer Ose, Alexandre C. Pereira, Mary C. Playdon, Lucilla Poston, Jackie Price, Qibin Qi, Kathryn Rexrode, Adam Risch, Joshua Sampson, Wei Jie Seow, Howard D. Sesso, Svati H. Shah, Xiao Ou Shu, Gordon C.S. Smith, Ulla Sovio, Victoria L. Stevens, Rachael Stolzenberg-Solomon, Toru Takebayashi, Therese Tillin, Ruth Travis, Ioanna Tzoulaki, Cornelia M. Ulrich, Ramachandran S. Vasan, Mukesh Verma, Ying Wang, Nick J. Wareham, Andrew Wong, Naji Younes, Hua Zhao, Wei Zheng, Steven C. Moore

Producción científica: Articlerevisión exhaustiva

76 Citas (Scopus)


The Consortium of Metabolomics Studies (COMETS) was established in 2014 to facilitate large-scale collaborative research on the human metabolome and its relationship with disease etiology, diagnosis, and prognosis. COMETS comprises 47 cohorts from Asia, Europe, North America, and South America that together include more than 136,000 participants with blood metabolomics data on samples collected from 1985 to 2017. Metabolomics data were provided by 17 different platforms, with the most frequently used labs being Metabolon, Inc. (14 cohorts), the Broad Institute (15 cohorts), and Nightingale Health (11 cohorts). Participants have been followed for a median of 23 years for health outcomes including death, cancer, cardiovascular disease, diabetes, and others; many of the studies are ongoing. Available exposure-related data include common clinical measurements and behavioral factors, as well as genome-wide genotype data. Two feasibility studies were conducted to evaluate the comparability of metabolomics platforms used by COMETS cohorts. The first study showed that the overlap between any 2 different laboratories ranged from 6 to 121 metabolites at 5 leading laboratories. The second study showed that the median Spearman correlation comparing 111 overlapping metabolites captured by Metabolon and the Broad Institute was 0.79 (interquartile range, 0.56-0.89).

Idioma originalEnglish (US)
Páginas (desde-hasta)991-1012
Número de páginas22
PublicaciónAmerican journal of epidemiology
EstadoPublished - jun 1 2019
Publicado de forma externa

ASJC Scopus subject areas

  • General Medicine


Profundice en los temas de investigación de 'The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies'. En conjunto forman una huella única.

Citar esto